Is RAPT Therapeutics, Inc. (RAPT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.3% / 30% | 13.8% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.3% / 33% | 13.8% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 1.9% / 33% | 96.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.3% / 33% | 13.8% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 1.9% / 33% | 96.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -85.4% | |
| Return on Assets (ROA) | -51.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$83M |
| Free Cash Flow | -$83M |
| Total Debt | $4M |
| Debt-to-Equity | 1.7 |
| Current Ratio | 12.0 |
| Total Assets | $240M |
Price & Trading
| Last Close | $58.02 |
| 50-Day MA | $49.94 |
| 200-Day MA | $27.42 |
| Avg Volume | 2.4M |
| Beta | 0.4 |
|
52-Week Range
$5.67
| |
About RAPT Therapeutics, Inc. (RAPT)
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is RAPT Therapeutics, Inc. (RAPT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), RAPT Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is RAPT Therapeutics, Inc.'s debt ratio?
RAPT Therapeutics, Inc.'s debt ratio is 0.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.9%.
What are RAPT Therapeutics, Inc.'s key financial metrics?
RAPT Therapeutics, Inc. has a market capitalization of $1.7B. Return on equity stands at -85.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.